Refine by
Dvt Articles & Analysis
14 news found
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a ...
Xarelto is approved for more venous and arterial thromboembolic (VAT) conditions than any other NOAC: The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors The treatment of pulmonary embolism (PE) in adults The treatment of deep vein thrombosis (DVT) in adults The prevention of recurrent PE ...
ByBayer AG
ITV’s Rags Martel explains how it works. WORLD'S FIRST DVT CLOT REMOVING PROCEDURE IN LONDON ...
Rivaroxaban Rivaroxaban, as an antithrombotic drug, is widely used in the treatment and prevention of deep vein thrombosis (DVT) symptoms prior to hip or knee replacement surgery, treatment of venous thromboembolism (VTE) and nonvalvular atrial fibrillation, as well as treatment of DVT and pulmonary embolism (PE). ...
The results confirm the excellent safety and effectiveness of the ClotTriever system in real-world DVT patients. Over 90% met the primary endpoint of complete or near-complete thrombus extraction and there was only one device-related serious adverse event. ...
CLOUT is the largest prospective mechanical thrombectomy study ever conducted in the field of DVT. The study evaluates the safety and effectiveness of the ClotTriever system including thrombus removal, hospital resource utilization, and long-term clinical results. ...
DEFIANCE is a randomized controlled trial (“RCT”) comparing the clinical outcomes of patients with iliofemoral deep vein thrombosis (“DVT”) treated with the ClotTriever System versus anticoagulation only. ...
Xarelto is approved for more venous and arterial thromboembolic (VAT) conditions than any other NOAC: The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors The treatment of pulmonary embolism (PE) in adults The treatment of deep vein thrombosis (DVT) in adults The prevention of recurrent PE ...
ByBayer AG
Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with injectable ...
ByBayer AG
Public reimbursement coverage reaches 9 Provinces in Canada Canadian private health plan coverage now exceeding 90% Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement (“PLA”) with Quebec Minister of Health, for ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the full approval of its Investigational Device Exemption (IDE) application by the FDA to conduct the pivotal STAR–D (Safe and Timely Antithrombotic Removal – Direct ...
Venous obstruction can occur as a result of different causes, including extrinsic compression because of malignancy or anatomic variation, and acute or chronic Deep Vein Thrombosis (DVT). “Commencement of patient enrollment in the VIVID Trial is a critical milestone in the development of the Vesper DUO Stent System,” said Bruce J. ...
Inceptus Medical LLC, a medical device company incubator, announced today that it has completed a $4.5M Series B financing for Okami Medical Inc. The financing will provide the resources to develop and commercialize innovative devices for the interventional treatment of cardiovascular disease. The financing was led by members of the board of directors, U.S. Venture Partners (USVP) and medical ...
The OptionELITE is the only IVC filter with FDA clearance for delivery via the popliteal vein, the same access site through which DVT treatment in the legs is commonly initiated. CLEANER is the only wall-contacting rotational thrombectomy system with FDA clearance for use in the peripheral vasculature, and also may be delivered via the popliteal vein to enable filter placement ...